Introduction
Recombinant Human IL36B, also known as IL-1F8, is a cytokine that belongs to the interleukin-1 (IL-1) family of proteins. It is produced by immune cells, such as monocytes, macrophages, and dendritic cells, and plays a crucial role in the regulation of inflammatory and immune responses. In this article, we will explore the structure, activity, and applications of Recombinant Human IL36B in detail.
Structure of Recombinant Human IL36B
Recombinant Human IL36B is a glycoprotein with a molecular weight of approximately 17 kDa. It is composed of 157 amino acids and contains a signal peptide at the N-terminus, which is cleaved during protein maturation. The mature form of IL36B consists of two domains: an N-terminal domain (NTD) and a C-terminal domain (CTD). The NTD contains four alpha helices, which are responsible for binding to the IL-36 receptor (IL-36R). The CTD contains a beta-trefoil fold, which is responsible for binding to the IL-1 receptor accessory protein (IL-1RAcP). This interaction between IL36B and its receptors is essential for its biological activity.
Activity of Recombinant Human IL36B
Recombinant Human IL36B is a proinflammatory cytokine that acts as an agonist for the IL-36 receptor complex, which consists of IL-36R and IL-1RAcP. Upon binding to its receptors, IL36B induces the production of other proinflammatory cytokines, such as IL-6, IL-8, and TNF-alpha, by activating the NF-kappaB and MAPK signaling pathways. This results in the recruitment and activation of immune cells, leading to inflammation and tissue damage.
IL36B is also involved in the regulation of adaptive immune responses. It can enhance the production of Th1 and Th17 cytokines, which are important for the activation of T cells and the differentiation of B cells. In addition, IL36B can also induce the expression of co-stimulatory molecules on antigen-presenting cells, which are essential for the activation of T cells.
Applications of Recombinant Human IL36B
Due to its proinflammatory and immunoregulatory properties, Recombinant Human IL36B has been studied extensively for its potential therapeutic applications. Some of the key areas of research include:
Autoimmune Diseases
IL36B has been shown to play a role in the pathogenesis of autoimmune diseases, such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. Therefore, targeting IL36B could be a potential therapeutic strategy for these diseases. In fact, preclinical studies have shown promising results in animal models of psoriasis, where IL36B blockade reduced skin inflammation and improved disease symptoms.
Inflammatory Disorders
IL36B has also been implicated in various inflammatory disorders, such as inflammatory bowel disease, asthma, and chronic obstructive pulmonary disease. In these conditions, IL36B contributes to tissue damage and inflammation. Therefore, targeting IL36B could potentially alleviate symptoms and improve disease outcomes.
Infectious Diseases
IL36B has been shown to play a role in the immune response against infectious diseases, such as viral and bacterial infections. Recombinant Human IL36B has been studied as a potential therapeutic agent for these infections, either alone or in combination with other treatments.
Cancer
Recent studies have also shown that IL36B may have anti-tumor effects by promoting the activation of immune cells and inhibiting tumor growth. This has led to the investigation of IL36B as a potential immunotherapy for cancer treatment.
Conclusion
In summary, Recombinant Human IL36B is a cytokine with diverse biological activities, including proinflammatory and immunoreg
There are no reviews yet.